269 related articles for article (PubMed ID: 30527920)
1. Myelodysplastic syndromes and acute myeloid leukemias in the elderly.
Mueller BU; Seipel K; Pabst T
Eur J Intern Med; 2018 Dec; 58():28-32. PubMed ID: 30527920
[TBL] [Abstract][Full Text] [Related]
2. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
[TBL] [Abstract][Full Text] [Related]
6. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.
Brandwein JM; Zhu N; Kumar R; Leber B; Sabloff M; Sandhu I; Kassis J; Olney HJ; Elemary M; Schuh AC
Am J Blood Res; 2017; 7(4):30-40. PubMed ID: 28804680
[TBL] [Abstract][Full Text] [Related]
7. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
8. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Talati C; Sweet K
Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
[TBL] [Abstract][Full Text] [Related]
9. New agents: great expectations not realized.
Lancet JE
Best Pract Res Clin Haematol; 2013 Sep; 26(3):269-74. PubMed ID: 24309529
[TBL] [Abstract][Full Text] [Related]
10. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
11. [What is recommended in the treatment of acute myeloid leukemia?].
Thol F
Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
[TBL] [Abstract][Full Text] [Related]
12. Reprise: gemtuzumab ozogamicin for older patients with acute myeloid leukemia.
Neuberg DS
J Clin Oncol; 2012 Nov; 30(32):3905-6. PubMed ID: 22987082
[No Abstract] [Full Text] [Related]
13. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
14. No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard medical research council induction chemotherapy.
Jensen MK
J Clin Oncol; 2013 May; 31(13):1700. PubMed ID: 23530103
[No Abstract] [Full Text] [Related]
15. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.
Nand S; Godwin J; Smith S; Barton K; Michaelis L; Alkan S; Veerappan R; Rychlik K; Germano E; Stiff P
Leuk Lymphoma; 2008 Nov; 49(11):2141-7. PubMed ID: 19021057
[TBL] [Abstract][Full Text] [Related]
19. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Tang K; Schuh AC; Yee KW
Curr Oncol Rep; 2021 Aug; 23(10):120. PubMed ID: 34350512
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin.
Przepiorka D; Deisseroth A; Kane R; Kaminskas E; Farrell AT; Pazdur R
J Clin Oncol; 2013 May; 31(13):1699-700. PubMed ID: 23530094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
